Cns Pharmaceuticals Stock Z Score
| CNSP Stock | USD 0.1 0 1.76% |
Cns | Z Score |
Cns Pharmaceuticals Company Z Score Analysis
Cns Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Cns Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Cns Pharmaceuticals is extremely important. It helps to project a fair market value of Cns Stock properly, considering its historical fundamentals such as Z Score. Since Cns Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cns Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cns Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Cns Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Cns Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cns Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cns Pharmaceuticals by comparing valuation metrics of similar companies.Cns Pharmaceuticals is currently under evaluation in z score category among its peers.
Cns Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Cns Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cns Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cns Pharmaceuticals' value.| Shares | Parallel Advisors, Llc | 2024-09-30 | 0.0 | Smith Anglin Financial, Llc | 2024-06-30 | 0.0 | Fmr Inc | 2024-09-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-06-30 | 0.0 | Anson Funds Management Lp | 2024-09-30 | 0.0 | Fsm Wealth Advisors, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 203.2 K | Ubs Group Ag | 2024-09-30 | 181.9 K |
Cns Fundamentals
| Return On Equity | -10.19 | ||||
| Return On Asset | -2.24 | ||||
| Current Valuation | (1.2 M) | ||||
| Shares Outstanding | 40.75 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 0.70 % | ||||
| Number Of Shares Shorted | 4.53 M | ||||
| Price To Earning | (13.70) X | ||||
| Price To Book | 1.71 X | ||||
| EBITDA | (18.86 M) | ||||
| Net Income | (18.85 M) | ||||
| Cash And Equivalents | 8.96 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 300.81 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | (2.98) X | ||||
| Cash Flow From Operations | (14.14 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (352.97) X | ||||
| Target Price | 0.5 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 5.28 M | ||||
| Total Asset | 1.7 M | ||||
| Retained Earnings | (69.57 M) | ||||
| Working Capital | (4.54 M) | ||||
| Current Asset | 6.61 M | ||||
| Current Liabilities | 488.66 K | ||||
| Net Asset | 1.7 M |
About Cns Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cns Stock
| 0.48 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
| 0.44 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.